Literature DB >> 17952379

The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA.

Si-Jin Liu1, Dao-Qiang Zhang, Xiu-Mei Sui, Lin Zhang, Zi-Wei Cai, Li-Qiu Sun, Ya-Jun Liu, Yan Xue, Guo-Fa Hu.   

Abstract

Osteopontin (OPN) is a secreted, non-collagenous, sialic acid-rich protein which functions by mediating cell-matrix interactions and cellular signaling via binding with integrins and CD44 receptors. An increasing number of studies have shown that OPN plays an important role in controlling cancer progression and metastasis. OPN was found to be expressed in many human cancer types, and in some cases, its over-expression was shown to be directly associated with poor patient prognosis. In vitro cancer cell line and animal model studies have clearly indicated that OPN can function in regulating the cell signaling that ultimately controls the oncogenic potential of various cancers. Previous studies in our laboratory demonstrated that OPN is highly expressed in human osteosarcoma (OS) cell line OS-732. In this study, we successfully reduced the tumorigenecity of OS-732 cells xenotransplanted into nude mice, using the antisense human OPN (hOPN) RNA expression vector.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952379      PMCID: PMC6275891          DOI: 10.2478/s11658-007-0031-0

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  8 in total

1.  Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo.

Authors:  Baogang J Xu; Wenwei Yan; Bojana Jovanovic; Aubie K Shaw; Qi A An; Jimmy Eng; Anna Chytil; Andrew J Link; Harold L Moses
Journal:  Cancer Microenviron       Date:  2010-04-13

2.  Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.

Authors:  Matthias Bache; Matthias Kappler; Henri Wichmann; Swetlana Rot; Antje Hahnel; Thomas Greither; Harun M Said; Matthias Kotzsch; Peter Würl; Helge Taubert; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-04-08       Impact factor: 4.430

3.  Inhibition of osteopontin dependent carcinogenesis.

Authors:  Shailendra Kapoor
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-20       Impact factor: 4.553

4.  Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262.

Authors:  Kun Song; Ning Liu; Yan Yang; Xue Qiu
Journal:  Tumour Biol       Date:  2015-12-03

Review 5.  Osteopontin as a biomarker for osteosarcoma therapy and prognosis.

Authors:  Xingwen Han; Wenji Wang; Jingjing He; Lei Jiang; Xun Li
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

6.  Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway.

Authors:  Xin Zi; Guoqiang Zhang; Shichao Qiu
Journal:  Epigenetics       Date:  2021-04-02       Impact factor: 4.528

Review 7.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

Review 8.  The interactome: predicting the protein-protein interactions in cells.

Authors:  Dariusz Plewczyński; Krzysztof Ginalski
Journal:  Cell Mol Biol Lett       Date:  2008-10-06       Impact factor: 5.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.